Leukemia Research

Papers
(The H4-Index of Leukemia Research is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Editorial Board51
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy26
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion26
New treatments for adult T-cell leukemia/lymphoma25
Long-term engraftment stability of umbilical cord blood cells preserved in −135 °C mechanical freezers24
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)23
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation21
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia20
ALK INHIBITOR PLUS VINBLASTINE FOR REFRACTORY/RELAPSED PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA: A PROSPECTIVE, ONE-ARM, OPEN-LABEL REAL-WORLD STUDY19
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT19
CLINICAL FEATURES AND TREATMENT OUTCOME OF CHILDREN WITH LYMPHOBLASTIC LYMPHOMA IN TAIWAN17
ANAPLASTIC LYMPHOMA KINASE INHIBITION ACTIVATES AUTOPHAGY IN ALK+ ANAPLASTIC LARGE CELL LYMPHOMA17
A CASE OF B-CELL LYMPHOBLASTIC LYMPHOMA WITH PRIMARY BONE INVOLVEMENT: A MIMICKER OF RHEUMATOLOGICAL AND INFECTIOUS DISEASE16
We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death15
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study14
0.10507798194885